ReviewCurrent oncology reports2005
Diffuse large B-cell lymphomas with plasmablastic differentiation.
Review in Current oncology reports, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 54 citations in OpenAlex.
- Plasmablastic Transformation of CLL/SLL: The Role of Early NGS Diagnosis and Targeted Multimodal Therapy.Diagnostics (Basel, Switzerland) · 2026Article
- Epstein-Barr virus-associated B-cell lymphoproliferative disorders and lymphomas: Diagnostic overlaps and defining features.Human pathology · 2025Review
- Follicular lymphoma suggested to transform into EBV-negative plasmablastic lymphoma.International journal of hematology · 2019Article
- Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients.Journal of hematology & oncology · 2015Article
- [CD20-negative primary intestinal diffuse large B-cell lymphoma:a case report and literature review].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2015Review
- Human immunodeficiency virus-negative plasmablastic lymphoma in the neck: a rare case report and literature review.European journal of medical research · 2014Article
- A case of plasmablastic lymphoma of the liver without human immunodeficiency virus infection.World journal of gastroenterology · 2013Article
- The cytological diagnosis of extra-oral plasmablastic lymphoma: a rare entity.Journal of clinical and diagnostic research : JCDR · 2013Article
- Plasmablastic lymphoma of the retroperitoneum in an HIV- and HCV-positive patient: hard to diagnose and harder to treat.Medical oncology (Northwood, London, England) · 2012Article
- CD20-negative de novo diffuse large B-cell lymphoma in HIV-negative patients: a matched case-control analysis in a single institution.Journal of translational medicine · 2012Article
- Orbital plasmablastic lymphoma: a clinico-pathological correlation of a rare disease and review of literature.Clinical ophthalmology (Auckland, N.Z.) · 2012Article
- ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature.Journal of hematology & oncology · 2009Review
- Prognostic Significance of in situ Phenotypic Marker Expression in Diffuse Large B-cell Lymphomas.Biomarker insights · 2007Article
- Nodal aggressive B-cell lymphomas: a diagnostic approach.Journal of clinical pathology · 2007Review
- Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities.Leukemia · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent evidence suggests that diffuse large B-cell lymphoma (DLBCL) with plasmablastic differentiation represents a clinically heterogeneous spectrum with different clinicopathologic characteristics representing distinct entities. Subtypes of DLBCL with plasmablastic features and terminal B-cell differentiation include plasmablastic lymphoma (PBL) of oral mucosa type; PBL with plasmacytic differentiation; primary effusion lymphoma (PEL); KSHV-positive solid lymphoma/extracavitary PEL/HHV-8 associated DLBCL; and DLBCL expressing ALK. In contrast, PBL associated with multicentric Castleman disease, DLBCL with secretory differentiation, pyothorax-associated lymphoma, and atypical Burkitt lymphoma with plasmacytoid differentiation have morphologic appearances of plasma cell differentiation but maintain a mature B-cell (CD20 positive) phenotype. These tumors as well as extramedullary plasmablastic tumors secondary to multiple myeloma or plasmacytomas are included in the differential diagnosis. In this review, we discuss recently described clinicopathologic insights, case observations, and recently reported molecules involved in terminal B-cell or plasma cell differentiation and their possible roles in disease pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.